FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a splicing modulator or a pharmaceutically acceptable salt thereof, a compound for treating a neoplastic disorder, conjugate of an antibody and a drug for treating a neoplastic disorder, a pharmaceutical composition for treating a neoplastic disorder, use of a splicing modulator or a pharmaceutically acceptable salt thereof, a compound or a conjugate of an antibody and a drug for treating a neoplastic disorder, use of a splicing modulator or a pharmaceutically acceptable salt thereof, a compound or a conjugate of an antibody and a drug for preparing a drug for treating a neoplastic disorder and a method of treating a subject having a neoplastic disorder or suspected presence thereof.
EFFECT: invention extends the range of splicing modulation means.
27 cl, 6 dwg, 14 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN ANTIBODIES BINDING TO ROR2 | 2018 |
|
RU2784586C2 |
| AIMED AT UPARAP ANTIBODY-DRUG CONJUGATES | 2017 |
|
RU2740311C2 |
| ANTIBODIES AND ANTIBODY-DRUG CONJUGATES SPECIFIC TO CD123 AND THEIR USE | 2018 |
|
RU2789150C2 |
| SITE-SPECIFIC HER2 ANTIBODY-DRUG CONJUGATES | 2016 |
|
RU2745565C2 |
| ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2806049C2 |
| ANTIBODIES AND ANTIBODY FRAGMENTS FOR SITE-SPECIFIC CONJUGATION | 2016 |
|
RU2757815C2 |
| METHODS OF OBTAINING, PURIFICATION AND COMPOSING OF ANTIBODY-DRUG CONJUGATES | 2019 |
|
RU2801229C2 |
| CONJUGATES OF BINDER AND ACTIVE SUBSTANCE (ADC) HAVING ENZYMATICALLY CLEAVABLE GROUPS | 2017 |
|
RU2761390C2 |
| COMPOSITIONS OF ANTIBODIES AGAINST ROR1 AND CORRESPONDING METHODS | 2017 |
|
RU2766190C2 |
| DRUG CONJUGATES FROM MONOCLONAL CMET BINDING AGENTS AND THEIR USE | 2019 |
|
RU2813828C2 |
